Innova Captab Limited revises FY 2025-26 financials and approves capacity expansion
Innova Captab · Pharmaceuticals & Biotechnology
Key highlights
- Revised audited standalone and consolidated financial results for year ended 31 March 2026 approved on 21-22 August 2026 with unmodified audit opinion.
- Brownfield expansion approved for Baddi manufacturing facility, adding 2 oral solid dosage production lines; investment of ₹45 crore over 18-22 months financed by bank credit and internal accruals.
- Corrections include deferred tax asset recognition, reclassification of financial liabilities, and adjustments in cash flow statements with no material impact on profits or equity.
Why it's rated notable: The filing states no capex amount for the Baddi expansion, so the level stays at medium, the system default without a figure.
Original filing
As per Regulations 30 Of The Listing Regulations, The Board Of The Company Had Approved A Brownfield Expansion
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other capex / expansion filings this fortnight
- Maharaja & Speedex India Limited raises manufacturing capacity to 72 lakh units/year
- Elin Electronics Q2 FY27 earnings report with 10% revenue growth and margin update
- HOAC Foods India Limited H1 FY27 Earnings Call Transcript dated November 5, 2026
- Gujarat State Fertilizers & Chemicals Limited Q2 FY27 Earnings Call Highlights
- Supriya Lifescience H1 revenue up 14.8% to ₹396.04 crore; Q2 profit falls
- V-MARC India Ltd announces Q2 & H1 FY27 unaudited financial results and review report
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.